CHEPLAPHARM Arzneimittel GmbH
CHEPLAPHARM Arzneimittel GmbH, a prominent player in the pharmaceutical industry, is headquartered in Greifswald, Germany. Founded in 1986, the company has established itself as a leader in the development, production, and distribution of high-quality generic and specialty pharmaceuticals. With a strong presence across Europe and expanding operations in various international markets, CHEPLAPHARM focuses on therapeutic areas such as oncology, cardiology, and neurology. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to the evolving needs of healthcare providers and patients. Notable achievements include strategic partnerships and a robust pipeline of generics that enhance patient access to essential medications. CHEPLAPHARM's dedication to excellence positions it as a trusted name in the pharmaceutical landscape, continually striving to improve health outcomes worldwide.
DitchCarbon Score
How does CHEPLAPHARM Arzneimittel GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CHEPLAPHARM Arzneimittel GmbH's score of 30 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CHEPLAPHARM Arzneimittel GmbH's reported carbon emissions
In 2023, CHEPLAPHARM Arzneimittel GmbH reported total carbon emissions of approximately 146,900 kg CO2e, comprising 130,900 kg CO2e from Scope 1 and 16,000 kg CO2e from Scope 2 emissions. The Scope 1 emissions included about 33,600 kg CO2e from mobile combustion and 95,000 kg CO2e from stationary combustion. In comparison, the previous year, 2022, saw total emissions of approximately 217,000 kg CO2e, with Scope 1 emissions at 111,000 kg CO2e and Scope 2 emissions at 106,000 kg CO2e. A significant achievement in 2023 was the implementation of measures that resulted in a remarkable 92% reduction in Scope 2 emissions, attributed to the transition to renewable energy sources for all electricity consumption at their German sites. This commitment to sustainability reflects CHEPLAPHARM's proactive approach to reducing its carbon footprint and enhancing environmental transparency. The company has not disclosed any Scope 3 emissions data, indicating a focus on direct and indirect emissions from their operations. Overall, CHEPLAPHARM's climate commitments demonstrate a strong dedication to reducing carbon emissions and promoting sustainable practices within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | - | 000,000 |
| Scope 2 | 323,000 | 000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CHEPLAPHARM Arzneimittel GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
